ABIOSA PHARMA AS: årsregnskap 2025 vs 2024
Another loss-making year
approved 2026-05-12; registry 2026-05-16; journal 2026 441934
Summary
What changed
Comparing Årsregnskap 2025 with 2024 for ABIOSA PHARMA AS. Revenue 0 NOK → 0 NOK (0.0%). Net result -250 NOK → -491 NOK. Equity -11.9k NOK → -12.4k NOK.
Pressures included: operating result weakened.
Also worth watching: thin equity buffer. All figures are taken from the published annual accounts for ABIOSA PHARMA AS.
At a glance
Scorecard
Revenue
0 NOK
0 NOK
0.0%
Operating result
-250 NOK
-491 NOK
-96.4%
Net result
-250 NOK
-491 NOK
-96.4%
Equity
-11.9k NOK
-12.4k NOK
-4.1%
Cash
4 443 NOK
3 952 NOK
-11.1%
Total assets
4 443 NOK
3 952 NOK
-11.1%
What deteriorated
-
↓
Operating result weakened
Operating result -250 NOK → -491 NOK. Calculated
Things to notice
-
·
Thin equity buffer
Equity ratio is -314.0% of assets — limited loss-absorbing capacity on a stand-alone basis. Interpretation